Core Insights - Healios K.K. is set to present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 4:00 PM GMT [1] - The company is a leading clinical stage biotechnology firm in Japan, focusing on regenerative medicine through stem cell technology [3] Company Overview - Healios K.K. specializes in developing therapies for diseases lacking effective treatment options, utilizing both somatic stem cells and induced pluripotent stem (iPS) cells [3] - The company is advancing MultiStem® (HLCM051), a proprietary cell product derived from adult bone marrow, which has shown anti-inflammatory and immunomodulatory properties [3] - MultiStem has been tested in late-stage clinical trials with hundreds of patients, demonstrating safety and suggested efficacy across multiple indications [3] - Healios is also developing HLCN061, a next-generation NK cell treatment for solid tumors, which has shown robust anti-tumor efficacy in animal models and is preparing for initial human testing [3] - The company has established a gene-edited "universal donor" iPS cell line aimed at developing treatments in various fields, including immuno-oncology and ophthalmology [3] - Healios was founded in 2011 and has been publicly listed on the Tokyo Stock Exchange since 2015 under the code 4593 [3]

Company Overview - HEALIOS K.K. is Japan's leading clinical stage biotechnology company focused on regenerative medicine using stem cells [2] - The company was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 under the code 4593 [2] Product Development - Healios is developing MultiStem® (HLCM051), a proprietary cell product derived from multipotent adult progenitor cells (MAPCs) from healthy adult donors, which has shown anti-inflammatory and immunomodulatory properties [2] - MultiStem has been tested in hundreds of patients in late-stage clinical trials and is manufactured at scale in 3D bioreactors, demonstrating safety and suggested efficacy across multiple indications [2] - The company aims to advance MultiStem globally for conditions such as ARDS, trauma, and ischemic stroke [2] - In the iPSC regenerative medicine field, Healios has developed HLCN061, a next-generation NK cell treatment for solid tumors enhanced through gene-editing, showing robust anti-tumor efficacy in animal models [2] - HLCN061 benefits from a scalable 3D bioreactor manufacturing process and is being prepared for initial human testing in collaboration with Akatsuki Therapeutics [2] - Healios has established a proprietary gene-edited "universal donor" induced pluripotent stem cell line for developing next-generation treatments in various severe unmet medical needs [2] Upcoming Events - Richard Kincaid, Chief Financial Officer of Healios, will present at the Chardan 9 Annual Genetic Medicines Conference on October 21, 2025, at 2:00 PM Eastern Time [1]